CPIX vs. ASMB, ONCT, BIOR, GDTC, BFRG, LUMO, SYBX, MEIP, LSTA, and ENLV
Should you be buying Cumberland Pharmaceuticals stock or one of its competitors? The main competitors of Cumberland Pharmaceuticals include Assembly Biosciences (ASMB), Oncternal Therapeutics (ONCT), Biora Therapeutics (BIOR), CytoMed Therapeutics (GDTC), Bullfrog AI (BFRG), Lumos Pharma (LUMO), Synlogic (SYBX), MEI Pharma (MEIP), Lisata Therapeutics (LSTA), and Enlivex Therapeutics (ENLV). These companies are all part of the "pharmaceutical preparations" industry.
Assembly Biosciences (NASDAQ:ASMB) and Cumberland Pharmaceuticals (NASDAQ:CPIX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Assembly Biosciences received 54 more outperform votes than Cumberland Pharmaceuticals when rated by MarketBeat users. Likewise, 59.21% of users gave Assembly Biosciences an outperform vote while only 45.28% of users gave Cumberland Pharmaceuticals an outperform vote.
Assembly Biosciences has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500. Comparatively, Cumberland Pharmaceuticals has a beta of 0.16, meaning that its stock price is 84% less volatile than the S&P 500.
19.9% of Assembly Biosciences shares are owned by institutional investors. Comparatively, 15.5% of Cumberland Pharmaceuticals shares are owned by institutional investors. 4.1% of Assembly Biosciences shares are owned by insiders. Comparatively, 43.3% of Cumberland Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Cumberland Pharmaceuticals has higher revenue and earnings than Assembly Biosciences. Cumberland Pharmaceuticals is trading at a lower price-to-earnings ratio than Assembly Biosciences, indicating that it is currently the more affordable of the two stocks.
Assembly Biosciences has a net margin of 0.00% compared to Assembly Biosciences' net margin of -15.87%. Assembly Biosciences' return on equity of 6.84% beat Cumberland Pharmaceuticals' return on equity.
In the previous week, Cumberland Pharmaceuticals had 19 more articles in the media than Assembly Biosciences. MarketBeat recorded 44 mentions for Cumberland Pharmaceuticals and 25 mentions for Assembly Biosciences. Cumberland Pharmaceuticals' average media sentiment score of -0.02 beat Assembly Biosciences' score of -0.20 indicating that Assembly Biosciences is being referred to more favorably in the media.
Summary
Assembly Biosciences beats Cumberland Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
Get Cumberland Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CPIX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CPIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cumberland Pharmaceuticals Competitors List
Related Companies and Tools
